Articles by G. Steven Burrill - BioPharm International

ADVERTISEMENT

ADVERTISEMENT

Articles by G. Steven Burrill

A Strong Start to 2012

Better news about the global economy buoys life-sciences funding.
Apr 1, 2012

Better news about the global economy buoys life-sciences funding.

Global Economic Woes Overshadow Biotech Industry Advances in 2011

Greater emphasis on focus and efficiency for companies as market demands value in 2012.
Jan 1, 2012

Greater emphasis on focus and efficiency for companies as market demands value in 2012.

Volatile Markets Take a Toll on Life-Sciences Initial Public Offerings

Volatile Markets Take a Toll on Life-Sciences Initial Public Offerings
Oct 1, 2011

Volatile Markets Take a Toll on Life-Sciences Initial Public Offerings

Biotech Posts Strong Gains

Strong pipelines, approvals, and deals drive up market cap.
Jul 1, 2011

Strong pipelines, approvals, and deals drive up market cap.

Biotech Starts the Year Positively

Industry starts the year with a positive spin.
Apr 1, 2011

Industry starts the year with a positive spin.

Biotech Writes its New "Play Book"

Business models that were used to create current value are no longer going to be effective going forward.
Jan 1, 2011

Business models that were used to create current value are no longer going to be effective going forward.

Biotech Cools Off as Capital Markets Weaken

Biotech's mid-sized elites position themselves for growth.
Oct 1, 2010

Biotech's mid-sized elites position themselves for growth.

Capital Market's Woes Weigh Heavily on Biotech

After a bright start to the year, some of biotech's blue chip companies have seen their early gains turn into losses.
Jul 1, 2010

After a bright start to the year, some of biotech's blue chip companies have seen their early gains turn into losses.

Biotech on a Roll to Start 2010

As the capital markets in the US and globally continue to strengthen, the biotech industry can expect to see a rise in initial public offerings this year.
Apr 1, 2010

As the capital markets in the US and globally continue to strengthen, the biotech industry can expect to see a rise in initial public offerings this year.

ADVERTISEMENT

ADVERTISEMENT

Click here